Abstract
As of January 22, 2020, a total of 571 cases of the 2019-new coronavirus (2019-nCoV) have been reported in 25 provinces (districts and cities) in China. At present, there is no vaccine or antiviral treatment for human and animal coronavirus, so that identifying the drug treatment options as soon as possible is critical for the response to the 2019-nCoV outbreak. Three general methods, which include existing broad-spectrum antiviral drugs using standard assays, screening of a chemical library containing many existing compounds or databases, and the redevelopment of new specific drugs based on the genome and biophysical understanding of individual coronaviruses, are used to discover the potential antiviral treatment of human pathogen coronavirus. Lopinavir /Ritonavir, Nucleoside analogues, Neuraminidase inhibitors, Remdesivir, peptide (EK1), abidol, RNA synthesis inhibitors (such as TDF, 3TC), anti-inflammatory drugs (such as hormones and other molecules), Chinese traditional medicine, such ShuFengJieDu Capsules and Lianhuaqingwen Capsule, could be the drug treatment options for 2019-nCoV. However, the efficacy and safety of these drugs for 2019- nCoV still need to be further confirmed by clinical experiments.
Keywords
CoronavirusMedicineLopinavirDrugAntiviral drugVirologyCoronavirus disease 2019 (COVID-19)PharmacologyPandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)OutbreakVirusViral loadInternal medicineInfectious disease (medical specialty)Antiretroviral therapyDisease
Affiliated Institutions
Related Publications
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epi...
Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human...
Structure of the RNA-dependent RNA polymerase from COVID-19 virus
The COVID-19 RNA-synthesizing machine Many in the scientific community have mobilized to understand the virus that is causing the global coronavirus disease 2019 (COVID-19) pand...
Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia
Abstract Background A novel coronavirus of zoonotic origin (2019-nCoV) has recently been identified in patients with acute respiratory disease. This virus is genetically similar...
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
Promising antiviral protease inhibitors With no vaccine or proven effective drug against the virus that causes coronavirus disease 2019 (COVID-19), scientists are racing to find...
Publication Info
- Year
- 2020
- Type
- article
- Volume
- 14
- Issue
- 1
- Pages
- 69-71
- Citations
- 1183
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
1183
OpenAlex
Cite This
Hongzhou Lu
(2020).
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
BioScience Trends
, 14
(1)
, 69-71.
https://doi.org/10.5582/bst.2020.01020
Identifiers
- DOI
- 10.5582/bst.2020.01020